The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

AIMS: We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor‐tyrosine kinase inhibitor osimertinib, in patients with advanced non‐small cell lung cancer in two Phase I, open‐label, two‐part clini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Vishwanathan, Karthick, Dickinson, Paul A., So, Karen, Thomas, Karen, Chen, Yuh‐Min, De Castro Carpeño, Javier, Dingemans, Anne‐Marie C., Kim, Hye Ryun, Kim, Joo‐Hang, Krebs, Matthew G., Chih‐Hsin Yang, James, Bui, Khanh, Weilert, Doris, Harvey, R. Donald
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980546/
https://ncbi.nlm.nih.gov/pubmed/29381826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13534
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados